PathAI has announced version 2.21 of AISight Dx, its digital pathology platform, adding dashboard configuration, AI-result visibility and a collection of controls for reviewing and organising pathology cases. The release focuses on everyday workflow and enterprise administration rather than introducing a new diagnostic algorithm.
AISight Dx is used to view, manage and collaborate on digitised pathology slides. PathAI describes the platform as cleared by the US Food and Drug Administration for primary diagnosis and CE-IVD marked for use in the European Economic Area, the United Kingdom and Switzerland. Those existing regulatory designations matter, but they should not be read as a fresh clearance for every feature in version 2.21.
A more configurable case workspace
The central interface change is a customisable case dashboard. Organisations can configure which information appears and how it is arranged, allowing a laboratory to bring the most relevant case fields closer to the point of review. PathAI has also added an AI Impressions widget intended to surface AI-derived information within the case workspace.
The announcement does not identify a newly cleared diagnostic model or claim that the widget independently makes a diagnosis. Healthcare organisations will therefore need to assess what information is presented, which algorithms supply it and how it fits within their approved clinical workflow. Human review, local validation and the intended-use documentation remain essential.
For slide work, version 2.21 adds bulk deletion of annotations, editable linear measurements and motion-based rotation. Pathologists and laboratory staff can also search for keyboard shortcuts, while collaboration invitations have been revised. These are incremental controls, but reducing repetitive navigation can matter in high-volume environments where a user may review many slides and cases each day.
Data organisation at enterprise scale
PathAI has expanded bulk ingestion metadata to include specimen, block and slide identifiers. Those fields can make it easier to preserve laboratory structure as cases move into the digital environment and can support downstream search, reconciliation and auditing. A new clinician preferences library gives administrators another way to standardise or preserve user-level settings.
The release also adds support for Amazon S3 Glacier Deep Archive. That storage tier is designed for long-term retention where retrieval is infrequent, so its value is likely to be archival cost management rather than immediate slide access. Laboratories should examine retrieval time, retention policy, regional storage, encryption and disaster-recovery implications before moving regulated records into an archive tier.
Together, the changes point to AISight Dx being developed as an operational platform around the diagnostic viewer, with controls spanning ingestion, review, collaboration, personalisation and retention. That breadth can help larger organisations, but it also makes change management important. Administrators will need to test configurations, document permissions and train users so the new options do not create inconsistent workflows.
What customers should verify
The official announcement lists capabilities but does not provide pricing, a detailed rollout schedule or performance measurements. Existing customers should confirm when version 2.21 reaches their environment, whether features are enabled by default and which functions require additional configuration or third-party services.
Clinical buyers should also separate platform usability improvements from claims about diagnostic accuracy. The update may make information easier to reach and cases easier to organise, yet the safety and effectiveness of a clinical workflow depend on the complete system, validated algorithms, scanners, displays, network and human procedures.
Version 2.21 is therefore best understood as a meaningful workflow and administration release for an already regulated digital pathology platform. Its practical impact will vary by laboratory scale and configuration, with the strongest benefits likely to come from careful integration into existing quality and governance processes.